Skip to main content

Table 1 Demographic and clinical characteristics of patients

From: Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

  Total N(748) 4 mg N(226) 8 mg N(509) <65 yr. N(418) ≥65 yr. N(330)
Gender (woman), % 83.5 83.5 73.7§ 84.9 65.8*
Age, mean (SD), yr 61.5(11.0) 61.2(11.1) 61.7(10.8) 53.9(8.1) 71.1(4.9)*
BMI, mean (SD), Kg/m2 26.6(3.4) 26.5(3.7) 26.6(3.3) 26.0(3.5) 27.3(3.2)*
OAB evolution time, mean (SD), d. 389.7(618.6) 405.6(695.7) 383.6(588.1) 316.5(388.6) 482.3(813.7)*
OAB-V8 score (0–40) 17.6(7.1) 17.4(7.4) 17.6(7.0) 17.4(7.1) 17.8(7.1)
Concomitant conditions, %   69.8 66.4 59.0 77.9*
Obesity (BMI ≥ 30 Kg/m2) 12.7 14.6 12.0 10.0 16.1§
HBP 45.1 45.1 45.4 34.7 58.2*
Urinary tract infections 19.7 18.1 20.0 21.3 17.6§
DM 20.6 21.2 19.8 17.5 24.5§
Depression 13.4 15.0 12.8 13.4 13.3
CVA 1.2 1.3 1.2 0.2 2.4§
Parkinson’s 1.2 1.3 1.0 0.5 2.1
Concomitant medication, % 67.3 69.8 66.4 59.0 77.9*
  1. SD Standard deviation; BMI Body Mass Index; OAB (overactive bladder); HBP High blood pressure; DM Diabetes mellitus; CVA Cerebrovascular Accident*p between groups < 0.001; §p between groups < 0.05.